GlaxoSmithKline plc: Company Analysis (Strategy, Portfolio and Pipeline Analysis) e

• Publication date: May 2011

Introduction This analysis examines the historical and projection performance for GlaxoSmithKline in the prescription pharmaceutical segment . The profile encompasses global industry player strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales projections for key drugs. Features and benefits * Gain insight into GlaxoSmithKline's strategic outlook across the next 6...

Introduction

This analysis examines the historical and projection performance for GlaxoSmithKline in the prescription pharmaceutical segment . The profile encompasses global industry player strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales projections for key drugs.

Features and benefits

* Gain insight into GlaxoSmithKline's strategic outlook across the next 6 years.
* Analyze industry player sales projections by product, therapy area, lifecycle stage, geography, molecule type and source.

Highlights

Strategic insight into the prospects for GlaxoSmithKline over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the firm 's prescription pharmaceuticals outlook using a variety of cuts of the historical and projection sales.

Your key questions answered

* Benchmark GlaxoSmithKline's performance against key rivals in the prescription pharmaceutical segment
* Assess GlaxoSmithKline's continued diversification strategy with vaccines and emerging industry s positioned as key growth opportunities.
* Analyse how life-cycle managment (and a lack of generic competition) will facilitate GSK's continued strong position in the global asthma/COPD industry .

Drug And Medication Industry

Executive Summary
Key findings
GlaxoSmithKline prescription pharma sales outlook
GlaxoSmithKline financial outlook
Key developments
[Missing title]
Upcoming developments
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Strategic Insight
Firms Introduction
Firms Sales
Firms Financials
Key Products
Data sourcing
Analyst consensus
STRATEGIC INSIGHT
Key findings
Strategic insight
Late-stage pipeline productivity continues to gather pace
Post-2007 pipeline traction provides important growth momentum
Sustainability of Seretide/Advair brand + Relovair launch should ensure continued leadership of global respiratory industry
Broad focused emerging industry s strategy key to long term revenue growth
COMPANY INTRODUCTION
Key findings
Background
Merger and Acquisition history
Glaxo and Wellcome
Smith Kline and Beecham
SmithKline Beecham
Key historical drug launches by component GSK firms
Post-2008 strategy
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and firm -reported total sales, 2004-10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16
KEY PRODUCTS
Overview
Seretide/Advair
Relovair
Avodart/Duodart
Lovaza
Tykerb/Tyverb
Benlysta
GSK1349572
Votrient
Vilanterol + GSK573719
Albiglutide
GlaxoSmithKline pipeline overview
APPENDIX
References
Abbreviations
Exchange rates